Clinical trials: NSCLC, Stage I
Carcinoma, Non-Small-Cell Lung
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
- Trial name
- VENUS-2 (NCT01683682)
- Testing
- BIBF 1120, Vinorelbine, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
NSCLC
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4 (CDK4) and CDK6 kinase activity. This open-label investigator-initiated trial (IIT) phase I study was designed to evaluate the safety and…
- Trial name
- EGFR (NCT06362980)
- Testing
- BPI-1178, Osimertinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- National Cancer Center, China
Non-small Cell Lung Cancer Stage I
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
Brief Summary The goal of this clinical trial is to evaluate the effect of postoperative adjuvant chemotherapy (ACT) in patients with stage I non-squamous non-small cell lung cancer (NSCLC) after curative resection.
- Trial name
- NCT07250360
- Testing
- Adjuvant chemotheapy
- Volunteers
- 2,072 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced/Recurrent Non-small-cell Lung Cancer
A Study of ARQ 197 in Combination With Erlotinib
This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in CYP2C19 poor metabolizer patients with advanced/recurrent…
- Trial name
- NCT01251796
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Lung Cancer
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280735
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103116
- Testing
- autologous dendritic cell cancer vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Edward Hirschowitz
Advanced Solid Tumors
A Study of TAS-116 in Patients With Solid Tumors
A First-in-Human (FIH) study of TAS-116 in patients with advanced solid tumors was first initiated in Japan in April 2014 and has been ongoing since then. The study consists of a dose escalation phase and a dose expansion phase.
- Trial name
- NCT02965885
- Testing
- TAS-116
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 31 people
- Sponsor
- Taiho Oncology, Inc.
NSCLC, Low Dose Radiotherapy
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
- Conditions
- NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
- Trial name
- NCT06431685
- Testing
- Whole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Local Advanced Non-Small Cell Lung Cancer
Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the recommended dose of pemetrexed and the maximum tolerated dose of radiotherapy when using concurrent pemetrexed/cisplatin/radiotherapy in the patients with local advanced non-small…
- Trial name
- NCT00846443
- Testing
- Concurrent Pemetrexed, Cisplatin and Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Locally Advanced Non Small Cell Lung Cancer (NSCLC)
Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
This is a two-center study which includes 24 patients maximum on 36 months : 24 months accrual - 12 months follow up. Eligible patients are included according to a standard 3+3 design.
- Trial name
- NCT01118676
- Testing
- cilengitide, radiochemotherapy
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Institut Claudius Regaud
Tumors Characterized by Genetic Abnormalities of ALK
A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
This study assessed the safety and efficacy of LDK378 in adult patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).
- Trial name
- NCT01283516
- Testing
- LDK378
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if escalated/accelerated proton radiotherapy can improve the control of Non-Small Cell Lung Cancer (NSCLC) and decrease side effects.
- Trial name
- NCT00495040
- Testing
- Proton Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Nonsmall Cell Lung Cancer
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
Based on the efficacy of immunotherapies in advanced disease with a reasonable safety profile/tolerability we could hypothesize that, immunotherapy should work best in the situation of minimal residual disease, Two clinical…
- Trial name
- PRINCEPS (NCT02994576)
- Testing
- Atezolizumab
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in…
- Conditions
- Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia, Stage IB Lung Cancer AJCC v8
- Trial name
- NCT04298606
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Trial name
- NCT07660055
- Testing
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving cryotherapy before surgery may kill more tumor cells. PURPOSE: This phase I trial is studying how well cryotherapy works in treating patients with primary stage I…
- Trial name
- NCT00890617
- Testing
- Cryotherapy (PTC), Prednisone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
NSCLC, Stage I, NSCLC, Stage II
The Role of Microbiota on the Development of Lung Cancer
Relationship between human microbiota and epidemiology of lung cancer
- Conditions
- NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III, NSCLC Stage IV
- Trial name
- NCT03454685
- Testing
- without intervention type
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiaorong Dong
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
KRN7000 in Treating Patients With Solid Tumors
RATIONALE: Biological therapies such as KRN7000 use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00003985
- Testing
- KRN7000
- Where
- 27 sites in Austria, Belgium and 7 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Trial name
- NCT03366766
- Testing
- Nivolumab, Cisplatin, Pemetrexed Disodium
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma, Non-small Sell Lung Cancer (NSCLC)
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v.
- Conditions
- Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer
- Trial name
- NCT02404441
- Testing
- PDR001
- Where
- 41 sites in United States, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Novartis Pharmaceuticals